HIV-1 associated neurologic disease is believed to be the result of a chronic inflammatory state, in which? soluble neurotoxic molecules, of both viral and cellular origin, act to cause neuronal injury and dysfunction.? We hypothesize that HIV-1 neurotoxicity is opposed by a number of endogenous pathways and mediators,? which serve to protect neurons. For example, neurotrophins can augment neuronal survival and function? through the activation of specific receptors (Trk receptors) and subsequent initiation of signaling cascades.? We therefore propose to study endogenous neuroprotective pathways that may provide us with new? therapeutic strategies for neuroAIDS. This will be achieved through two specific aims.
In Aim 1, experiments? will focus on signaling pathways associated with neurotrophin receptor activation, including analyses of the? neuroprotective effects of inhibitors of mixed lineage kinases (MLK)-3, p38 kinase and c-Jun NH2 terminal? kinases (JNK), as well as peptidomimetic Trk ligands. Effects on the survival and function of neurons? exposed to candidate HIV-1 neurotoxins will be evaluated, as will effects on monocyte/microglial activation.? In the second aim, we will evaluate the cell signaling events that are modulated in response to the inhibition? of MLK-3, using both pharmacological and genetic approaches. These experiments will take advantage of? available dominant negative mutants and MLK-3 knockout mice (to genetically target MLK-3), as well as? extant pharmacologic compounds and new, highly specific MLK-3 blockers that will be developed by our? commercial partner. Collectively, these investigations will identify novel neuroprotective strategies that may? enhance neuronal function and survival in neuroAIDS. Results from these studies will be correlated with? intracellular signaling events that occur in response to drug treatment, in order to identify new therapeutic? targets..
| Olson, Katherine E; Bade, Aditya N; Namminga, Krista L et al. (2018) Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. J Neurovirol 24:398-410 |
| Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26 |
| Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443 |
| Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154 |
| Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137 |
| Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276 |
| McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
| Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40 |
| Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65 |
| Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev : |
Showing the most recent 10 out of 203 publications
